Evidence map›Paper›PMID 32956392›Full record

ArticlePloS one2020

Evaluation of choroidal thickness in prodromal Alzheimer's disease defined by amyloid PET.

Alicia López-de-Eguileta, Carmen Lage, Sara López-García, Ana Pozueta, María García-Martínez, Martha Kazimierczak, María Bravo, María de Arcocha-Torres, Ignacio Banzo, Julio Jimenez-Bonilla and 5 more

Open access · goldAbstract readValidation Study
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Ocular changes as potential biomarkers for early diagnosis of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  5. Article
  6. Article
  7. Alzheimer's disease pathophysiology in the Retina.Progress in retinal and eye research · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Retinal Biomarkers for Alzheimer Disease: The Facts and the Future.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Alicia López-de-EguiletaDepartment of Ophthalmology, 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla', Santander, Spain.ORCID 0000-0001-8648-5077
Carmen LageNeurology Department and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla', Santander, Spain.
Sara López-GarcíaNeurology Department and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla', Santander, Spain.
Ana PozuetaNeurology Department and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla', Santander, Spain.
María García-MartínezNeurology Department and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla', Santander, Spain.
Martha KazimierczakNeurology Department and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla', Santander, Spain.
María BravoNeurology Department and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla', Santander, Spain.
María de Arcocha-TorresNuclear Medicine Department, University Hospital Marqués de Valdecilla, University of Cantabria, Molecular Imaging Group-IDIVAL, Santander, Spain.
Ignacio BanzoNuclear Medicine Department, University Hospital Marqués de Valdecilla, University of Cantabria, Molecular Imaging Group-IDIVAL, Santander, Spain.
Julio Jimenez-BonillaNuclear Medicine Department, University Hospital Marqués de Valdecilla, University of Cantabria, Molecular Imaging Group-IDIVAL, Santander, Spain.
Andrea CerveróDepartment of Ophthalmology, 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla', Santander, Spain.
Alexander GoikoetxeaDepartment of Anatomy, University of Otago, Dunedin, New Zealand.
Eloy Rodríguez-RodríguezNeurology Department and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla', Santander, Spain.
Pascual Sánchez-JuanNeurology Department and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla', Santander, Spain.
Alfonso CasadoDepartment of Ophthalmology, 'Marqués de Valdecilla' University Hospital, University of Cantabria, Institute for Research 'Marqués de Valdecilla', Santander, Spain.
Universidad de Cantabria · ESUniversity of Otago · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess and compare the involvement of choroidal thickness (CT) in patients with mild cognitive impairment (MCI) and dementia due to Alzheimer's disease (AD) defined by amyloid PET and healthy controls (HC).

methodsSixty-three eyes from 34 AD patients [12 eyes (19.0%) with dementia and 51 eyes (80.9%) with MCI], positive to 11C-labelled Pittsburgh Compound-B with positron emission tomography (11C-PiB PET/CT), and the same number of sex- and age-paired HC were recruited. All participants underwent enhanced depth imaging optical coherence tomography (EDI-OCT) assessing CT at 14 measurements from 2 B-scans. Paired Student t-test was used to compare CT measurements between MCI, dementia and sex- and age-paired HC. A univariate generalized estimating equations model (GEE) test was performed to compare MCI and dementia individually with all HC included.

resultsCompared with HC, eyes from patients with positive 11C-PiB PET/CT showed a significant CT thinning in 5 selected locations (in foveal thickness in vertical scan, in temporal scan at 1500μm, in superior scan at 500μm and in inferior scan at 1000μm and 1500μm, p = 0.020-0.045) whilst few significant CT reduction data was reported in MCI or dementia individually versus HC. However, the GEE test identified significant CT thinning in AD compared with all HC included (p = 0.015-0.046).

conclusionsTo our knowledge, the present study is the first measuring CT in eyes from MCI and dementia eyes positive to 11C-PiB PET/CT reporting a significant trend towards CT thinning in MCI patients which became more pronounced in dementia stage. We support further investigation involving larger and prospective OCT studies in AD population characterized with available biomarkers to describe whether choroidal vascular damage occurs specifically in prodromal stages of AD.

Indexed as

Prodromal SymptomsTomography, Optical CoherenceAgedAlzheimer DiseaseAmyloidAniline CompoundsAnthropometryArea Under CurveCarbon RadioisotopesCase-Control StudiesChoroidCognitive DysfunctionCross-Sectional StudiesDisease ProgressionEarly DiagnosisFemale2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloidAniline CompoundsCarbon-11Carbon RadioisotopesRadiopharmaceuticalsThiazoles

Identifiers

PMID32956392
PMCPMC7505462
OpenAlexW3087141712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.